1-dan master of the unyielding fist of Bayesian inference
3021 stories
·
0 followers

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

1 Share
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis submitted by /u/akejavel to r/DrugNerds
[link] [comments]
Read the whole story
clumma
3 hours ago
reply
Berkeley, CA
Share this story
Delete

Gilead, Sangamo strike $3B off-the-shelf CAR-T deal

1 Share
Gilead’s Kite has struck a $3 billion deal to access Sangamo Therapeutics’ zinc finger nuclease (ZFN) technology. Kite will use the ZFN gene editing platform to create next-generation, off-the-shelf CAR-T therapies to cement its position as a long-term front runner in the growing cell therapy space.
Read the whole story
clumma
6 hours ago
reply
Berkeley, CA
Share this story
Delete

GW cannabinoid drug fails midphase epilepsy trial

1 Share
GW Pharmaceuticals’ GWP42006 has failed to outperform placebo in a phase 2a focal seizure trial. The setback wiped 5% off GW’s stock and dented the prospects of the cannabidivarin candidate.
Read the whole story
clumma
6 hours ago
reply
Berkeley, CA
Share this story
Delete

Arcus Biosciences eyes $100M IPO

1 Share
Mere months after bagging $107 million in its series C round, Arcus Biosciences is teeing up for a $100 million IPO, which will drive the clinical development of its lead assets into 2020.
Read the whole story
clumma
16 hours ago
reply
Berkeley, CA
Share this story
Delete

Merck inks $394M takeover of oncolytic virus play Viralytics

1 Share
Merck is set to pay $394 million to acquire Viralytics. The takeover will give Merck control of an oncolytic immunotherapy that Viralytics is testing in combination with Keytruda in early-phase trials.
Read the whole story
clumma
16 hours ago
reply
Berkeley, CA
Share this story
Delete

AbbVie doubles down on tau with Voyager Alzheimer's deal

1 Share
AbbVie has teamed up with Voyager Therapeutics on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimer’s disease candidate.
Read the whole story
clumma
1 day ago
reply
Berkeley, CA
Share this story
Delete
Next Page of Stories